Results 151 to 160 of about 535,193 (240)
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz +8 more
wiley +1 more source
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley +1 more source
Erectile dysfunction in male elderly: A functionalanatomical review
The older we are, the bigger the possibility to be inflicted with erectile dysfunction. This could be related to various factors a/o: psychological, neurological, endorinological, vascular and iatrogenical etc.
Syamsir, Muhammad
core
Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams +3 more
wiley +1 more source
Abstract Background Clinical services for adults with early‐onset type 2 diabetes (EOT2D) are in urgent need of improvement. Methods We evaluated a multi‐disciplinary clinic for individuals with EOT2D at high risk (HbA1c >9%/triglyceride >20 mmol/L), providing 2–3 flexibly arranged consultations per individual between March 2024 and September 2025 ...
Jonathan Goldney +14 more
wiley +1 more source
Followup Results of a Combination of Calcitonin Gene-Related Peptide and Prostaglandin E1 in the Treatment of erectile Dysfunction. [PDF]
Kuczyk, M. +7 more
core +1 more source
ABSTRACT Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder caused by a defect of glycosylphosphatidyl‐anchored proteins, leading to an uncontrolled complement‐mediated hemolysis. The advent of complement inhibitors in clinical practice radically changed patients' outcomes and survival.
Bruno Fattizzo +8 more
wiley +1 more source
Abstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Allison C. Hyland +7 more
wiley +1 more source
Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives
Pierre Costa1, Thierry Grivel2, Naji Gehchan31Service d’Urologie–Andrologie, Hôpital Caremeau, Nîmes, France; 2159, Avenue Sainte-Marguerite, Nice, France; 3Eli Lilly and Company, Lilly France – Medical ...
Pierre Costa +2 more
core
Abstract Introduction It remains unclear which cardiovascular disease (CVD) risk scores are optimized for people living with treated HIV with high rates of viral suppression. We evaluated the performance of commonly used CVD risk scores in a population of primarily well‐treated HIV patients in England.
Ming Jie Lee +23 more
wiley +1 more source

